Investor Presentation February 2025 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future results of operations and financial position, including the underlying assumptions of any such project ...

Financial Data and Key Metrics Changes - For Q4 2025, revenue was $194.8 million, with Adjusted EBITDA at $65 million, leading to a full year revenue of $796.9 million, reflecting a 1% year-over-year increase [20] - Full year Adjusted EBITDA was $270.5 million, representing a 4% growth over 2024 [20] - Revenue from Pharma Direct increased to $151.4 million, up 41% year-over-year, driven by deeper sell-through at manufacturers and growth in consumer direct pricing [21] Business Line Data and Key Metrics Changes - Subscription revenue decreased by 3% year-over-year to $83.8 million, although early adoption of condition-specific subscriptions, particularly for weight loss, exceeded expectations [21] - The core marketplace remains foundational, but the company is increasingly focusing on Pharma Manufacturer Solutions as a key growth driver [9][11] Market Data and Key Metrics Changes - Monthly Active Consumers fell by 14% in 2025 compared to the previous year, but the company expects this number to stabilize from Q4 2025 through Q4 2026 [24] - The company reported nearly 25 million consumers and over 1 million healthcare professionals using its platform annually [11] Company Strategy and Development Direction - The company is evolving its business model to focus on Pharma Direct and Employer Direct offerings, which are seen as key growth opportunities [19][25] - The strategy aligns with the increasing consumer demand for direct-to-consumer healthcare solutions and the evolving dynamics of prescription access and pharmacy economics [7][25] Management's Comments on Operating Environment and Future Outlook - Management noted that affordability pressures and policy dynamics are reshaping access and pricing in healthcare, which plays to the company's strengths [7] - The company anticipates revenue pressure in 2026 due to strategic investments aimed at long-term durability, with Pharma Direct revenue expected to grow at least 30% year-over-year [23][24] Other Important Information - The company ended the year with $261.8 million in cash and approximately $80 million in unused capacity under its revolving credit facility [22] - The company repurchased approximately 48.9 million shares at an average price of $4.45 per share, totaling $217.4 million, signaling management's confidence in the company's future [22] Q&A Session Summary Question: Can you elaborate on the revenue guidance and unit economics? - Management explained that the decline in revenue is driven by the loss of significant revenue from Rite Aid and a shift of claims to Pharma Direct, which is reflected in the growth of point-of-sale programs [29][30] Question: How is the Pharma budget spending environment affecting new programs? - Management noted that spending has been pulled forward this year, with pharmaceutical manufacturers continuing to invest in direct-to-consumer programs [42][44] Question: What is the future of the legacy business amidst the focus on Pharma Direct? - Management confirmed that the core Rx Marketplace will remain foundational, but there is a strategic shift towards direct-to-consumer experiences as consumer preferences evolve [51][52] Question: How is the company addressing margin pressure? - Management indicated that while there is margin pressure, the focus is on stabilizing the underlying volume of scripts and renegotiating lower fees for long-term predictability [30][74] Question: What changes are being made to sales and marketing efforts in 2026? - Management stated that marketing spend will be redirected towards specific programs, with a focus on optimizing return on advertising spend [83][86]

Financial Data and Key Metrics Changes - For Q4 2025, revenue was $194.8 million, and Adjusted EBITDA was $65 million, leading to a full year revenue of $796.9 million, which is a 1% increase year-over-year [18] - Full year Adjusted EBITDA was $270.5 million, reflecting a 4% growth over 2024 [18] - Prescription transactions revenue declined by 6% year-over-year to $544 million, impacted by the Rite Aid bankruptcy and lower volume through an Integrated Savings Program partner [18][19] - Subscription revenue decreased by 3% year-over-year to $83.8 million, although early adoption of condition-specific subscriptions showed promise [19] - Revenue from Pharma Direct increased to $151.4 million, up 41% year-over-year, driven by deeper sell-through at manufacturers [20] Business Line Data and Key Metrics Changes - Pharma Manufacturer Solutions has become a key growth engine, with full year revenue up more than 40% in 2025 [7] - The company expanded its e-commerce ecosystem, tripling its retail footprint and achieving an 83% increase in order volume quarter-over-quarter [13] - Condition-specific subscriptions, particularly for weight loss, have shown strong early adoption, indicating potential for future revenue growth [19][14] Market Data and Key Metrics Changes - The healthcare landscape has seen intensified affordability pressures and evolving policy dynamics, which have reshaped access and pricing [5] - The growth of GLP-1 treatments for weight management has accelerated direct-to-consumer models, increasing consumer expectations for transparency and convenience [8] Company Strategy and Development Direction - The company is evolving its business model to focus more on Pharma Manufacturer Solutions as a key growth driver, reflecting changes in prescription access and pharmacy economics [6] - GoodRx is positioning itself as a digital storefront for self-pay and direct-to-consumer strategies, which are becoming central to prescription access [9] - The introduction of Employer Direct aims to help employers address gaps in traditional insurance coverage, expanding affordability and access [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategic direction, emphasizing the alignment with current healthcare trends and the importance of adapting to consumer-driven models [24] - The company anticipates pressure on prescription transactions revenue in 2026 but expects Pharma Direct revenue to grow at least 30% year-over-year [22][23] - Monthly active consumers fell by 14% in 2025, but management expects stabilization in 2026 [23] Other Important Information - The company ended the year with $261.8 million in cash and approximately $80 million in unused capacity under its revolving credit facility [21] - Share repurchases totaled $217.4 million, signaling management's confidence in the company's future [21] Q&A Session Summary Question: Can you elaborate on the revenue guidance and unit economics? - Management noted that the decline in prescription transaction revenue is due to the loss of significant revenue from Rite Aid and a shift of claims to Pharma Direct, which is expected to stabilize over time [28][29] Question: How is the pharma budget spending environment affecting Pharma Direct programs? - Management observed that spending has been pulled forward this year, with pharmaceutical manufacturers continuing to invest in direct-to-consumer programs [40][41] Question: What is the future of the legacy business amidst the focus on Pharma Direct? - Management confirmed that the core Rx Marketplace will remain foundational, but the focus is shifting towards direct-to-consumer experiences and partnerships with pharmaceutical manufacturers [48][50] Question: How will margin pressure manifest in the upcoming year? - Management indicated that while there may be margin pressure, investments in new offerings and a focus on long-term relationships with pharmacies will help stabilize the business [70][72]